Skip to Content
  • Small Proteins: Into the Gap

    We medicinal chemists are used to thinking about small molecule drugs – it’s what we do. And we’re also comfortable with having a category in… Read More
  • The Old School

    I enjoyed this piece on “The Changing Culture of Chemistry”. The author, Bruce Gibb of Tulane, has in mind the changes that are apparent when you re… Read More
  • More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a… Read More
  • When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the… Read More
  • Silicon Stays in the Shadows

    I like this review, but I’ve seen it before. Well, not this exact manuscript, but every few years it seems there’s another one with a similar title… Read More
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • Song of Experience

    I noticed this paper when it came out, and filed it in my “Useful Lab Tricks” folder. Organic chemists who have used triphenylphosphine-driven react… Read More
  • Watch Your Covalent Drugs Carefully

    EGFR is a growth-factor receptor protein that’s well known as a cancer target, and there are a number of drugs that target its kinase activity in order to… Read More
Page 4 of 17« First...23456...10...Last »